This activity allows companies to present their noteworthy new products and services through live presentations. Seating is available on a first-come, first-served basis. The Industry-Expert Theater content and views expressed therein are those of the companies and not of ASTRO.
Lunch or other food and beverages may be provided by the companies, which may subject you to reporting under the Federal Sunshine Act (the Open Payments Program) or other state laws. Otherwise, food may be available for purchase prior to the start of an event in the concessions area.
Theater 1
12:00 p.m. - 1:00 p.m. | BioProtect
Beyond the Gels: It’s Time to Rethink Your Rectal Spacer
Contact: Catherine Scanlon
Email: [email protected]
Theater 2
12:00 p.m. - 1:00 p.m. | Blue Earth Diagnostics, Inc.
POSLUMA (flotufolastat F 18) Injection Overview and Case Study Review
Contact: Maura Harrigan
Email: [email protected]
Room 1/2, Exhibition Level
12:00 p.m. - 1:00 p.m. | GE HealthCare
Converging Beams: Radiation Therapy meets Radioligand Therapy
Contact: Anne Clement
Email: [email protected]
Theater 1
2:00 p.m. - 3:00 p.m. | GammaTile
Reproducibility Matters: Clinical Insights from Radiation Oncologists Using GammaTile
Contact: Kyrie Kulkarni
Email: [email protected]
Theater 2
2:00 p.m. - 3:00 p.m. | PreludeDx
From Clin-Path to Precision in Early-Stage Breast Cancer: How New Genomic and Multi-Omic Risk Assessments Impact Your Radiation Treatment Decisions and Your Practice
Contact: Lindsey Fields
Email: [email protected]
Room 1/2, Exhibition Level
2:00 p.m. - 3:00 p.m. | Accuray
Case-Based Contouring and Treatment Planning with Clinical Experts
Contact: Sancie Nakarat
Email: [email protected]
Theater 1
12:00 p.m. - 1:00 p.m. | Boston Scientific
10 Years of SpaceOAR: A Decade of Data, A New Era of Evidence, and the Next Chapter for SpaceOAR Hydrogels
Contact: Sari Stockhaus
Email: [email protected]
Theater 2
12:00 p.m. - 1:00 p.m. | Lantheus
Seeing clearly: A Panel discussion on Real-World Cases of PSMA PET as a part of Prostate Cancer Management
Contact: Karen Huffman
Email: [email protected]
Room 1/2, Exhibition Level
12:00 p.m. - 1:00 p.m. | MIM Software, A GE HealthCare Company
Personalized Care in Perspective
Contact: Ashley Hanley
Email: [email protected]
Theater 1
3:00 p.m. - 4:00 p.m. | Pfizer/Astellas (PADCEV)
A Standard of Care Across 1L la/mUC: A review of the EV-302 trial and 30-Month Follow-Up Results
Contact: Sasan Jahanian
Email: [email protected]
Theater 2
3:00 p.m. - 4:00 p.m. | Servier Pharmaceuticals
Targeted Therapy in mIDH Adult-Type Diffuse Glioma
Contact: Kerry Adams
Email: [email protected]
Room 1/2, Exhibition Level
3:00 p.m. - 4:00 p.m. | Leo Cancer Care
Upright Radiotherapy: From Vision to Reality
Contact: Fiona Redford
Email: [email protected]
Theater 1
12:00 p.m. - 1:00 p.m. | Telix Pharmaceuticals
PSMA PET/CT in Radiation Oncology: Practical Pearls & Clinical Insights
Contact: Jessica Watcke
Email: [email protected]
Theater 2
12:00 p.m. - 1:00 p.m. | Novartis Pharmaceuticals Corporation
Advancing Treatment in mCRPC: What Radiation Oncologists and Nuclear Medicine Specialists Should Know about PLUVICTO, the First and Only PSMA-Targeted Therapy after One ARPI
Contact: Shannon Wenger
Email: [email protected]
Room 1/2, Exhibition Level
12:00 p.m. - 1:00 p.m. | AstraZeneca
Immunotherapy in the Treatment of Small Cell Lung Cancer
A Treatment Option for Certain Patients With Unresectable Stage III NSCLC
Contact: Kathleen Kurth
Email: [email protected]
Theater 2
2:00 p.m. - 3:00 p.m. | Interventional Oncology at Johnson & Johnson
Pharma and Medtech Synergy with Radiation Oncology
Contact: Heidi Souerwine
Email: [email protected]
Room 1/2, Exhibition Level
2:00 p.m. - 3:00 p.m. | Merck & Co., Inc.
A Treatment Option for Certain Patients with Locally Advanced HNSCC
Contact: Carmen de Gourville
Email: [email protected]
